• COMPANY
  • PRODUCTS
  • SUPPLY
  • IR

SUPPLY

Manufacturing Sites

Stable supply system of 3 plants with high production capacity

Towa has total of 11 billion tablets with 3 plants combined, Osaka, Okayama, and Yamagata Plant.
We have additional space in the building which we can manufacture up to 14 billion tablets. We are now constructing a system to boost our manufacturing capacity to cope with the increasing demand. For the purpose of the stable supply of Towa’s products, the products of oral formulations are separated in 3 portions, and each portion is allocated to 1 of the plants, respectively. On the other hand, injectable are manufactured only at a building with quake-absorbing structure in Yamagata Plant. These measures and policies minimize the disaster risk. The 3 plants in compliance with PIC/S GMP achieve high quality and stable supply of products and to support the future with trust.
Osaka plant serves as a tablet technology plant responsible for introducing new products with general formulations, while Okayama plant serves as a mass production technology plant for handling various products including capsules, powders, and granules. Yamagata plant serves as a comprehensive technology plant handling solid formulations, sterile formulations, and their high potent active pharmaceuticals.

3 Plants Overview

Osaka Plant
masking technology figure
Manufacturing
Capacity
2.5 billion
Manufacturing
Capabilities
Tablets
Okayama Plant
masking technology figure
Manufacturing
Capacity
5 billion
Manufacturing
Capabilities
Tablets, Powder, Granules, Capsules
Yamagata Plant
masking technology figure
Manufacturing
Capacity
4 billion(Up to 6.5 billion can be produced)
Manufacturing
Capabilities
Tablets, Powders, Granules, Capsules, Injections

Injections are manufactured only at a building of quake-absorbing structure in Yamagata Plant.

Visiting the highly clean manufacturing environment.

Towa has tour route exclusively designed for visitors at our Plants. Under high-level manufacturing environment, visitors can observe the leading the edge clean manufacturing facilities with their own eyes.
Towa will continue to ensure reliability on the generic industry by opening to medical professionals to see the environment where generic drugs are manufactured.

  • masking technology figure
  • masking technology figure
  • masking technology figure